Nov 30 (Reuters) - Novavax:
* NOVAVAX SAYS U.S./MEXICO COVID-19 PHASE 3 TRIAL EXPECTED TO BEGIN IN THE COMING WEEKS
* NOVAVAX - HAS BEEN WORKING CLOSELY WITH FDA TO COMPLETE TRIAL-INITIATION GATING ACTIVITIES RELATED TO COMMERCIAL-SCALE PRODUCTION IN NORTH CAROLINA
* NOVAVAX - WILL USE VACCINE MATERIAL PRODUCED AT COMMERCIAL SCALE FOR U.S./MEXICO COVID-19 PHASE 3 TRIAL
* NOVAVAX SAYS PIVOTAL COVID-19 PHASE 3 TRIAL IN UK & PHASE2B EFFICACY TRIAL IN SOUTH AFRICA COMPLETES ENROLLMENT
* NOVAVAX - INTERIM DATA IN COVID-19 PHASE 3 TRIAL IN UK EXPECTED AS SOON AS EARLY Q1 2021, ALTHOUGH TIMING DEPENDS ON COVID-19 RATE IN THE REGION
* NOVAVAX, ON COVID-19 PHASE 2B TRIAL IN SOUTH AFRICA, SAYS AVAILABILITY OF EFFICACY DATA DEPENDS ON ILLNESS RATE & MAY BE AVAILABLE AS SOON AS Q1 2021
* NOVAVAX - MORE THAN 25% OF ENROLLEES IN COVID-19 PHASE 3 TRIAL IN UK ARE OVER THE AGE OF 65
* NOVAVAX - ADDITIONAL CLINICAL DATA FROM COVID-19 PHASE 2 TRIAL IN U.S., AUSTRALIA EXPECTED TO BE UNBLINDED IN Q1, WILL BE TARGETED FOR PUBLICATION